Estimated impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: A modelling study
Narimane Nekkab, Raquel Lana, Marcus Lacerda, Thomas Obadia, Andre Siqueira, Wuelton Monteiro, Daniel Villela, Ivo Mueller, Michael White
PLOS MEDICINE | PUBLIC LIBRARY SCIENCE | Published : 2021
BACKGROUND: Despite recent intensification of control measures, Plasmodium vivax poses a major challenge for malaria elimination efforts. Liver-stage hypnozoite parasites that cause relapsing infections can be cleared with primaquine; however, poor treatment adherence undermines drug effectiveness. Tafenoquine, a new single-dose treatment, offers an alternative option for preventing relapses and reducing transmission. In 2018, over 237,000 cases of malaria were reported to the Brazilian health system, of which 91.5% were due to P. vivax. METHODS AND FINDINGS: We evaluated the impact of introducing tafenoquine into case management practices on population-level transmission dynamics using a ma..View full abstract
Awarded by NHMRC Principal Research Fellowship
NN, MW, DV, and RL received funding from the Medicines for Malaria Venture (https://www.mmv.org/). NN has been in part supported by the Pasteur-Roux-Cantarini Fellowship by Institut Pasteur (https://research.pasteur.fr/en/call/pasteur-roux-cantarini-fellowship_call-for-application_ 2019-autumn-session/). NN, IM, andMWare supported by the Supporting Preparedness in the Asia-Pacific Region through Knowledge (SPARK) project under the ASEAN-Pacific Infectious Disease and Response program (APIDDaR) (https://www.spark.edu.au/). IM is supported by NHMRC Principal Research Fellowship (GNT1155075) (https://www.nhmrc.gov.au/funding/find-funding/research-fellowships). DV is a CNPq/Brazil research fellow (https://www.gov.br/cnpq/pt-br).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.